<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772588</url>
  </required_header>
  <id_info>
    <org_study_id>15-334</org_study_id>
    <secondary_id>c15-164</secondary_id>
    <nct_id>NCT02772588</nct_id>
  </id_info>
  <brief_title>AASUR in High Risk Prostate Cancer</brief_title>
  <official_title>ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether anti-testosterone medications, when&#xD;
      administered before, during, and after high-dose, precision radiation, will be effective in&#xD;
      preventing the prostate cancer from returning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with biochemical failure</measure>
    <time_frame>36 months</time_frame>
    <description>Biochemical failure is defined as an increase in PSA by more than 2ng/mL above the nadir value. PSA rise equals or exceeds 2ng/mL will be the date of failure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>patients with prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARN-509</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
    <other_name>apalutamide</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic, ultra-fractionated radiotherapy</intervention_name>
    <arm_group_label>patients with prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytologic evidence of adenocarcinoma of the prostate confirmed at&#xD;
             local institution.&#xD;
&#xD;
          -  At least one of the following:&#xD;
&#xD;
          -  Two or more high risk features OR&#xD;
&#xD;
          -  Gleason score 8-10&#xD;
&#xD;
          -  PSA ≥20 ng/mL within two months prior to registration&#xD;
&#xD;
          -  Clinical Stage ≥T3 disease, as determined by standard digital rectal examination (DRE)&#xD;
&#xD;
          -  Radiographic stage ≥T3 disease as determined by a ≥75% probability of extracapsular&#xD;
             extension or seminal vesicle invasion per reading radiologist&#xD;
&#xD;
          -  Any Gleason 9 or 10 disease OR &gt;4 cores of Gleason 8 disease&#xD;
&#xD;
          -  KPS ≥ 70%&#xD;
&#xD;
          -  IPSS (International Prostate Symptom Score) ≤ 20F&#xD;
&#xD;
          -  Patient must be available for follow-up&#xD;
&#xD;
          -  Laboratory test findings within 28 days of study registration :&#xD;
&#xD;
          -  Adequate hepatic function:&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times the upper institutional limits of normal (ULN). Patients with a&#xD;
             history of Gilbert's syndrome may be enrolled if the total bilirubin is &lt; 3 mg/dL with&#xD;
             a predominance of indirect bilirubin. If the total bilirubin is &gt;1.5 x the&#xD;
             institutional ULN, direct and indirect bilirubin will be measured and if direct&#xD;
             bilirubin is ≤ 1.5 x the institutional ULN, the patient will be eligible to&#xD;
             participate&#xD;
&#xD;
          -  SGPT (ALT) and SGOT (AST) ≤ 2.5 x ULN&#xD;
&#xD;
          -  Adequate renal function with creatinine &lt;2.0 x the institutional ULN&#xD;
&#xD;
          -  Adequate hematologic function:&#xD;
&#xD;
          -  Absolute neutrophil counts ≥ 1500 cell/mm3&#xD;
&#xD;
          -  Platelets ≥ 100,000 cells/mm3 (independent of blood transfusion and/or growth factors&#xD;
             within 3 months prior to registration)&#xD;
&#xD;
          -  Hemoglobin value ≥9 g/dL at the Screening Visit (independent of blood transfusion&#xD;
             and/or growth factors within 3 months prior to registration)&#xD;
&#xD;
          -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
          -  Potassium ≥ 3.5 mmol/L&#xD;
&#xD;
          -  Patients with pelvic and/or retroperitoneal lymph nodes &lt; 1.5 cm in short axis are&#xD;
             eligible as they are not considered to have definitive metastases&#xD;
&#xD;
          -  Willing and able to provide written informed consent and HIPAA authorization for the&#xD;
             release of personal health information NOTE: HIPAA authorization may be either&#xD;
             included in the informed consent or obtained separately&#xD;
&#xD;
          -  Males 18 years of age and above&#xD;
&#xD;
          -  The effects of apalutamide, abiraterone, leuprolide and stereotactic,&#xD;
             ultra-hypofractionated radiation on the developing human fetus at the recommended&#xD;
             therapeutic dose are unknown. Men (including men with vasectomies) must agree to use&#xD;
             adequate contraception (a condom and another effective method of birth control) prior&#xD;
             to registration, for the duration of study participation, and for at least 3 months&#xD;
             thereafter. Men must also agree not to donate sperm for the duration of study&#xD;
             participation, and for at least 3 months thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiographic evidence of metastatic disease&#xD;
&#xD;
          -  Patients with one or more positive lymph nodes as determined by radiographic&#xD;
             assessment of MRI or CT NOTE: lymph nodes noted on MRI or CT to be &gt; 1.5 cm on the&#xD;
             short axis will require review by the local reference radiologist per institutional&#xD;
             RECIST review practices. If the lymph nodes are considered suspicious on repeat&#xD;
             review, they must be confirmed negative for study participation&#xD;
&#xD;
          -  Prior treatment for prostate cancer; this includes any prior surgery (including&#xD;
             Transurethral resection of the prostate (TURP), prostate cancer treatment),&#xD;
             chemotherapy, radiation, or anti-androgen therapy/androgen deprivation therapy with&#xD;
             the following exception: patients who will have been on LHRH Agonist/Antagonist&#xD;
             Therapy for &lt;/= 1 month prior to registration are permitted to enroll with study PI&#xD;
             approval.&#xD;
&#xD;
          -  Prior use of steroidal antiandrogens (megestrol acetate, cyproterone acetate), AR&#xD;
             partial agonists, ketoconazole, chemotherapy, immunotherapy, estrogens,&#xD;
             radiopharmaceuticals within 3 months before registration&#xD;
&#xD;
          -  Prior use of non-steroidal anti-androgens (e.g., bicalutamide, flutamide, nilutamide)&#xD;
             within 1 month before registration&#xD;
&#xD;
          -  Prior treatment with medications known to lower the seizure threshold within 4 weeks&#xD;
             of registration (see section 5.5.2 apalutamide for a list of prohibited medications)&#xD;
&#xD;
          -  History of another malignancy within the previous 3 years except for the following:&#xD;
             adequately treated basal cell or squamous cell skin cancer, superficial bladder&#xD;
             cancer, adequately treated Stage I or Stage II cancer currently in complete remission,&#xD;
             or any other cancer that has been in complete remission for at least 3 years&#xD;
&#xD;
          -  Severe hepatic impairment (Child-Pugh Class C)&#xD;
&#xD;
          -  Concurrent treatment with strong CYP3A4 inducers (e.g., phenytoin, carbamazepine,&#xD;
             rifampin, rifabutin, rifapentine, phenobarbital)&#xD;
&#xD;
          -  Major surgery within 4 weeks of registration&#xD;
&#xD;
          -  Presence of a pacemaker&#xD;
&#xD;
          -  Active infection or other medical condition that would make prednisone use&#xD;
             contraindicated&#xD;
&#xD;
          -  A known hypersensitivity to abiraterone acetate, apalutamide, and prednisone and/or&#xD;
             any of their excipients&#xD;
&#xD;
          -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart&#xD;
             failure, arterial or venous thromboembolic events (e.g., pulmonary embolism,&#xD;
             cerebrovascular accident including transient ischemic attacks), or clinically&#xD;
             significant ventricular arrhythmias within 6 months prior to registration.&#xD;
&#xD;
          -  Seizure or known condition that may pre-dispose to seizure (including but not limited&#xD;
             to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior&#xD;
             to randomization, brain arteriovenous malformation; or intracranial masses such as&#xD;
             schwannomas and meningiomas that are causing edema or mass effect)&#xD;
&#xD;
          -  Any ECG changes that interfere with QT interval interpretation (e.g., left bundle&#xD;
             branch block, frequent premature ventricular contractions)&#xD;
&#xD;
          -  Prolonged QTc &gt;450ms at the Screening Visit&#xD;
&#xD;
          -  Uncontrolled diabetes, heart disease, hypertension&#xD;
&#xD;
          -  Gastrointestinal disorder that may affect absorption of study treatment&#xD;
&#xD;
          -  Active symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
          -  History of pituitary or adrenal dysfunction&#xD;
&#xD;
          -  Active Infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or&#xD;
             other medical condition that would make prednisone/prednisolone corticosteroid) use&#xD;
             contraindicated&#xD;
&#xD;
          -  Patients with Crohn's disease or ulcerative colitis&#xD;
&#xD;
          -  Patients that cannot tolerate MRI&#xD;
&#xD;
          -  Inability to have fiducial markers placed&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator, would preclude participation in&#xD;
             this study&#xD;
&#xD;
          -  Enrollment concurrently in another investigational drug study or within 4 weeks of&#xD;
             registration&#xD;
&#xD;
          -  Concurrent treatment with strong CYP3A4 inducers (e.g., phenytoin, carbamazepine,&#xD;
             rifampin, rifabutin, rifapentine, phenobarbital)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean M McBride, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARN-509</keyword>
  <keyword>Abiraterone</keyword>
  <keyword>Leuprolide</keyword>
  <keyword>Intensity-Modulated and Image-Guided Radiation Therapy</keyword>
  <keyword>15-334</keyword>
  <keyword>apalutamide,</keyword>
  <keyword>JNJ-56021927</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

